Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Caribou Biosciences, Inc. (CRBU : NSDQ)

• Company Description    Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif. Number of Employees: 147

• Price / Volume Information    Yesterday's Closing Price: $1.80 Daily Weekly Monthly 20 Day Moving Average: 689,180 shares Shares Outstanding: 93.12 (millions) Market Capitalization: $167.62 (millions) Beta: 2.54 52 Week High: $3.00 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.00% -11.58% 12 Week 40.63% 27.74% Year To Date 13.21% 7.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2929 7TH STREET SUITE 105 - BERKELEY,CA 94710 USA ph: 510-982-6030 fax: - investor.relations@cariboubio.com http://www.cariboubio.com

• General Corporate Information    Officers Rachel E. Haurwitz - Chief Executive Officer; President Sriram Ryali - Chief Financial Officer Scott Braunstein - Director Andrew Guggenhime - Director Dara Richardson-Heron - Director Peer Information Caribou Biosciences, Inc. (CORR.) Caribou Biosciences, Inc. (RSPI) Caribou Biosciences, Inc. (CGXP) Caribou Biosciences, Inc. (BGEN) Caribou Biosciences, Inc. (GTBP) Caribou Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 142038108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 93.12 Most Recent Split Date: (:1) Beta: 2.54 Market Capitalization: $167.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 1.85% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.01 Price/Cash Flow: - Price / Sales: 18.38 EPS Growth vs. Year Ago Period: 16.67% vs. Previous Quarter: 18.60% Sales Growth vs. Year Ago Period: -23.01% vs. Previous Quarter: 13.34% ROE 06/30/25 - -62.35 03/31/25 - -55.70 12/31/24 - -50.21 ROA 06/30/25 - -49.65 03/31/25 - -45.35 12/31/24 - -41.49 Current Ratio 06/30/25 - 6.66 03/31/25 - 7.63 12/31/24 - 7.16 Quick Ratio 06/30/25 - 6.66 03/31/25 - 7.63 12/31/24 - 7.16 Operating Margin 06/30/25 - -1,568.03 03/31/25 - -1,490.84 12/31/24 - -1,491.94 Net Margin 06/30/25 - -1,800.93 03/31/25 - -1,490.84 12/31/24 - -1,491.94 Pre-Tax Margin 06/30/25 - -1,801.03 03/31/25 - -1,490.94 12/31/24 - -1,492.04 Book Value 06/30/25 - 1.79 03/31/25 - 2.34 12/31/24 - 2.79 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©